Skip to main content
. 2022 Jan 27;10(2):204. doi: 10.3390/vaccines10020204

Figure 5.

Figure 5

Impact of HPV DNA ((A) p = 0.26 at Log-Rank) and of p16 expression ((B) IRS ≥ 4 cut-off p = 0.049 at Log-Rank; (C) IRS ≥ 6 cut-off p = 0.26 at Log-Rank) on relapse free survival of primarily operated patients (HPV DNA was available in 66 cases, p16 IHC in 73).